Thomas Eigentler
Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
Bochem J, Weide B, Pawelec G, Garbe C, Meier F, Terheyden P, Uslu U, Wagner N, Eigentler T, Soffel D, Spreuer J, Amaral T, Zelba H, Wistuba-Hamprecht K. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PloS one 2019; 14:e0221301.
Aug 16, 2019Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
Aug 16, 2019PloS one 2019; 14:e0221301
Bochem Jonas, Weide Benjamin, Pawelec Graham, Garbe Claus, Meier Friedegund, Terheyden Patrick, Uslu Ugur, Wagner Nikolaus, Eigentler Thomas, Soffel Daniel, Spreuer Janine, Amaral Teresa, Zelba Henning, Wistuba-Hamprecht Kilian
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Klein C, Keller U, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C, Bergmann T, Bockmeyer C, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Heinzerling L. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PloS one 2013; 8:e53745.
Jan 14, 2013The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Jan 14, 2013PloS one 2013; 8:e53745
Voskens Caroline J, Mateus Christine, Mohr Peter, Paetzold Sylvie, Satzger Imke, Schadendorf Dirk, Schlaeppi Marc, Schuler Gerold, Schuler-Thurner Beatrice, Trefzer Uwe, Ulrich Jens, Vaubel Julia, von Moos Roger, Weder Patrik, Wilhelm Tabea, Göppner Daniela, Dummer Reinhard, Klein Christina, Keller Ullrich, Goldinger Simone M, Loquai Carmen, Robert Caroline, Kaehler Katharina C, Berking Carola, Bergmann Tanja, Bockmeyer Clemens L, Eigentler Thomas, Fluck Michael, Garbe Claus, Gutzmer Ralf, Grabbe Stephan, Hauschild Axel, Hein Rüdiger, Hundorfean Gheorghe, Justich Armin, Heinzerling Lucie M
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients
Meier F, Garbe C, Knaudt B, Zielinski C, Leiter U, Forschner A, Eigentler T, Clasen S, Guenova E, Berneburg M. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. J Am Acad Dermatol 2009; 60:863-8.
May 1, 2009Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients
May 1, 2009J Am Acad Dermatol 2009; 60:863-8
Meier Friedegund, Garbe Claus, Knaudt Björn, Zielinski Christina, Leiter Ulrike, Forschner Andrea, Eigentler Thomas, Clasen Stephan, Guenova Emmanuella, Berneburg Mark